Designing Prodrugs and Bioprecursors

The Practice of Medicinal Chemistry

Volumn , Issue , 2008, Pages 721-746

  Wermuth, Camille G ^a  

^a Prestwick Chemical Inc   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 67649879923     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-374194-3.00036-6     Document Type: Chapter

References (162)

1. Stella V. Pro-drugs: an overview and definition. Pro-drugs as a Novel Drug Delivery System 1975, Vol. 14:1-115. American Chemical Society, Washington, DC. T. Higuchi, V. Stella (Eds.).
2. Sinkula A.A. Prodrugs, protective groups and the medicinal chemist. Medicinal Chemistry 1977, Vol. 5:125-133. Elsevier, Amsterdam. J. Mathieu (Ed.).
3. Wermuth C.G. Designing prodrugs and bioprecursors. The Practice of Medicinal Chemistry 2003, 561-585. Academic press, London. C.G. Wermuth (Ed.).
4. Ettmayer P., Amidon G.L., Clement B., Testa B. Lessons learned from marketed and investigational prodrugs. J. Med. Chem. 2004, 47:2393-2403.
5. Testa B. Prodrug objectives and design. Comprehensive Medicinal Chemistry II 2007, Vol. 5:1009-1041. Elsevier, Amsterdam. J.B. Taylor, D.J. Triggle (Eds.).
6. Albert A. Chemical aspects of selective toxicity. Nature (London) 1958, 182:421-423.
7. Harper N.J. Drug latentiation. J. Med. Pharm. Chem. 1959, 1:467-500.
8. Wermuth C.G. Bioprécurseurs contre prodrogues. Drug Metabolism and Drug Design: Quo Vadis? 1983, 253-271. Sanofi-Clin-Midy, Montpellier. M. Briot, W. Cautreels, R. Roncucci (Eds.).
9. Wermuth C.G. Designing prodrugs and bioprecursors. Drug Design: Fact or Fantasy? 1984, 47-72. Academic Press, London. G. Jollès, K.R.H. Wooldrige (Eds.).
10. Wermuth C.G. Les prodrogues, des médicaments plus sûrs et plus maniables. Bull. Soc. Pharm. Bordeaux. 1980, 119:107-129.
11. Wermuth C.G. Modulation of natural substances in order to improve their pharmacokinetic properties. Natural Products as Medicinal Agents 1981, 185-216. Hippokrates Verlag, Stuttgart. J.L. Beal, E. Reinhard (Eds.).
12. Daehne W.V., Frederiksen E., Gundersen E., Lund F., March P., Petersen H.J., Roholt K., Tybring L., Godtfredsen W.O. Acyloxymethyl esters of ampicillin. J. Med. Chem. 1970, 13:607-612.
13. Bodin N.O., Ekström B., Forsgren U., Jalar L.P., Magni L., Ramsey C.H., Sjöberg B. Bacampicillin: a new orally well-absorbed derivative of ampicillin. Antimicrob. Agents Chemother. 1975, 8:518-525.
14. Clayton J.P., Cole M., Elson S.W., Ferres H., Hanson J.C., Mizen L.W., Sutherland R. Preparation, hydrolysis, and oral absorption of lactonyl esters of penicillins. J. Med. Chem. 1976, 19(12):1385-1391.
15. Testa B., Jenner P. Drug Metabolism, Chemical and Biochemical Aspects 1976, Marcel Dekker, New York.
16. Shen T.I., Witzel B.E., Jones H., Linn B.O., McPherson J., Greenwald R., Fordice M., Jacobs A. Synthesis of a new antiinflammatory agent, cis -5-fluoro-2-methyl-1-[ p -(methylsulfinyl) benzylidenyl]-indene-3-acetic acid. Fed. Proc. 1972, 31:577.
17. Hucker H.B., Stauffer S.C., White S.D., Rhodes R.A., Arrison B.H., Umbenhauer E.R., Bower R.J., McMahon F.G. Physiological disposition and metabolic fate of a new anti-inflamatory agent, cis -5-fluoro-2-methyl-1-[ p -(methylsulfinyl) benzylidenyl]-indene-3-acetic acid in the rat, dog, rhesus monkey, and man. Drug Metab. Dispos. 1973, 1:721-736.
18. Duggan D.E., Hare L.E., Ditzler C.A., Lei B.W., Kwan K.C. The disposition of sulindac. C lin. Pharmacol. Ther. 1977, 21:326-335.
19. Duggan D.E., Hooke K.F., Noll R.M., Hucker H.B., Van Arman C.G. Comparative biodisposition of sulindac and metabolites in five species. Biochem. Pharmacol. 1978, 27:2311-2320.
20. Duggan D.E., Hooke K.F., Risley E.A., Shen T.Y., Van Arman C.G. Identification of the biologically active form of sulindac. J. Pharmacol. Exp. Ther. 1977, 201(1):8-13.
21. Drabek J., Neumann R. Proinsecticides. Progress in Pesticide Biochemistry and Toxicology 1985, Vol. 5:35-86. John Wiley & Sons, Ltd., Chichester. D.H. Hutson, T.R. Roberts (Eds.).
22. Higuchi T., Stella V. Pro-drugs as novel drug delivery systems 1975, Vol. 14. American Chemical Society, Washington, DC.
23. Bundgaard H. Design and application of prodrugs. A Textbook of Drug Design and Development 1991, 113-191. Harwood Academic Publishers, Chur. 1st Edition. P. Krogsgaard-Larsen, H. Bundgaard (Eds.).
24. McClure D. The effect of a pro-drug of epinephrine (dipivaloylepinephrine) in glaucoma-general pharmacology, toxicology and clinical experience. Pro-Drugs as a Novel Drug Delivery Systems 1975, Vol. 14:224-235. American Chemical Society, Washington, DC. T. Higuchi, V. Stella (Eds.).
25. Horn A.S. Pro-drugs of dopaminergic agonists. C hemistry and Industry 1980, 12:441-444.
26. Westerink B.H.C., Dijkstra D., Feenstra M.G.P., Grol C.J., Horn A.S., Rollema H., Wirix E. Dopaminergic prodrugs: brain concentration and neurochemical effects of 5,6- and 6,7-ADTN after administration as dibenzoyl esters. Eur. J. Pharmacol. 1980, 61:7-15.
27. Tullar B.F., Minatoya H., Lorenz R.R. Esters of N-tert-butylarterenol. Long-acting new bronchodilators with reduced cardiac effects. J. Med. Chem. 1976, 19:834-838.
28. Lin T.S. Synthesis and in vitro antiviral activity of 3'-O-acyl derivatives of 5'-amino-2'-deoxy thymidine: potential prodrugs for topical application. J. Pharm. Sci. 1984, 73:1568-1571.
29. Harnden M.R., Jarvest R.L., Boyd M.R., Sutton D., Verehodge R.A. Prodrugs of the selective antiherpesvirus agent 9-[4-hydroxy-3-(hydroxymethyl)but-1-yl]guanine (BRL 39123) with improved gastrointestinal absorption properties. J. Med. Chem. 1989, 32:1738-1743.
30. Jones L.A., Moorman A.R., Chamberlain S.D., Miranda P.d., Reynolds D.J., Burns C.L., Krenitsky T.A. Di- and triester prodrugs of the varicella-zoster antiviral agent 6-methoxypurine arabinoside. J. Med. Chem. 1992, 35:56-63.
31. Bodor N., Sloan K.B., Little R.J., Selk S.H., Caldwell L. Soft drugs 4. 3-Spirothiazolidines of hydrocortisone and its derivatives. Int. J. Pharm. 1982, 10:307-321.
32. Collis A.J. Drug access and prodrugs. Medicinal chemistry-the role of organic chemistry in drug research 1993, 61-82. Academic Press, London. 2nd Edition. C.R. Ganellin, S.M. Roberts (Eds.).
33. Anden N.E., Corrodi H., Dahlström A., Fuxe K., Högfelt T. Effects of tyrosine hydroxylase inhibition on the amine levels of central monoamine neurons. Life Sci. 1966, 5:561-568.
34. Anonymous. Etilevodopa. Drugs Fut. 26 (2001) 219-223.
35. Frey H.H., Popp C., Löscher W. Influence of inhibitors of the high affinity GABA uptake on seizure threshold in mice. Neuropharmacology 1979, 18:581-590.
36. Ulm E.H., Hichens M., Gomez H.J., Till A.E., Hand E., Vassil T.C., Biollaz J., Brunner H.R., Schelling J.L. Enalapril maleate and a lysine analogue (MK-521): disposition in man. Br. J. Pharmacol. 1982, 14:357-362.
37. Swanson B.L., Vlasses P.H., Ferguson R.K., Berquist P.A., Till A.E., Irvin J.D., Harris K. Influence of food on the bioavailability of enalapril. J. Pharm. Sci. 1984, 73:1655-1657.
38. Zannad F. Trandolapril: how does it differ from other angiotensin converting enzyme inhibitors?. Drugs 1993, 46:172-183.
39. Tsybina N., Ostrovskaya R.U., Protopova T.V., Parin V.V., Selezneva N.I., Skolainov A.P. Synthesis and pharmacological activity of gamma-aminobutyric acid derivatives. Khim. Pharm. Zh. 1974, 17:10-13.
40. Ostrovskaya R.U., Parin V.V., Tsybina N.M. The comparative neurotropic potency of gamma-aminobutyric acid and its cetyl ester. Byul. Eksp. Biol. Med. 1972, 73:51-55.
41. Beardsley, G. P., Rosowsky, A. Effect of methotrexate γ-monohexadecylester (γ-MHxMTX) on nucleoside uptake by human leukemic cells. In Proc. Am. Assoc. Cancer Res. 21, 71 Meeting, 1980, p. 264.
42. Wermuth C.G., Gaignault J.-C., Marchandeau C. Designing prodrugs and bioprecursors I: carrier prodrugs. The Practice of Medicinal Chemistry 1996, 671-696. Academic Press, London. C.G. Wermuth (Ed.).
43. Jones G. Lipoidal pro-drug analogues of various anti-inflammatory agents. Chem. Ind. (London), 1980, 452-456.
44. Jansen A.B.A., Russel T.J. Some novel penicillin derivatives. J. Chem. Soc. 1965, 2127-2132.
45. Binderup E., Godtfredsen W.O., Roholt K. Orally active cephaloglycinesters. J. Antibiot. 1971, 24:767-773.
46. Saari W.S., Halczenko W., Cochran D.W., Dobrinska M.R., Vincek W.C., Titus D.C., Gaul S.L., Sweet C.S. 3-Hydroxy-α-methyltyrosine progenitors: synthesis and evaluation of some (2-oxo-1,3-dioxol-4-yl)methyl esters. J. Med. Chem. 1984, 27:713-717.
47. Falch E., Krogsgaard-Larsen P., Christensen A.V. Esters of isoguvacineas potential prodrugs. J. Med. Chem. 1981, 24:285-289.
48. Svahn C.M., Merenyi F., Karlson L., Widlund L., Grälls M. Tranexamic acid derivatives with enhanced absorption. J. Med. Chem. 1986, 29:448-453.
49. Torriani H. Talniflumate. Drugs Fut 1979, 4:448-450.
50. Torriani H. Talmetacin. Drugs Fut 1982, 7:823-824.
51. Alexander J., Fromtling R.A., Bland J.A., Pelak B.A., Gilfillan E.C. (Acyloxy)alkyl carbamate prodrugs of norfloxacin. J. Med. Chem. 1991, 34:78-81.
52. Ahlmark M., Vepsaelaeinen J., Taipale H., Niemi R., Jaervinen T. Bisphophonate prodrugs: synthesis and in vitro evaluation of novel clodronic acid dianhydrides as bioreversible prodrugs of clodronate. J. Med. Chem. 1999, 42:1473-1476.
53. Aicher T.D., Bebernitz G.R., Bell P.A., Brand L.J., Dain J.G., Deems R., Fillers W.S., Foley J.E., Knorr D.C., Nadelson J., Otero D.A., Simpson R., Strohschein R.J., Young D.A. Hypoglycemic prodrugs of 4-(2,2-dimethyl-1-oxopropyl)benzoic acid. J. Med. Chem. 1999, 42:153-163.
54. Young D.A., Ho R.S., Bell P.A., Cohen D.K., McIntosh R.H., Nadelson J., Foley J.E. Inhibition of hepatic glucose production by SDZ 51641. Diabetes 1990, 39:1408-1413.
55. Walsh D.A., Moran H.W., Shamblee D.A., Welstead W.J., Nolan J.C., Sancilio L.F., Graff G. Antiinflammatory agents. 4. Syntheses and biological evaluation of potential prodrugs of 2-amino-3-benzoylbenzeneacetic acid and 2-amino-3-(4-chlorobenzoyl)benzene eacetic acid,. J. Med. Chem. 1990, 33:2296-2304.
56. Galzinga L., Garbin L., Bianchi M., Marzotto A. Properties of two derivatives of γ-aminobutyric acid (GABA) capable of abolishing cardiazol- and bicuculline-induced convulsions in the rat. Arch. Int. Pharmacodyn. 1978, 235:73-85.
57. Ahtee L., Halmekoski J., Heinonen H., Koskimies A. Comparison of the central nervous system actions of taurine and N -pivaloyltaurine. Br. J. Pharmacol. 1979, 66(3). 480 pages.
58. Kaplan J.P., Raizon B., Desarmenien M., Feltz P., Headley P.M., Worms P., Lloyd K.G., Bartholini G. New anticonvulsants: Schiff bases of γ-aminobutyric acid and γ-aminobutyramide. J. Med. Chem. 1980, 23:702-704.
59. Jensen N.P., Friedman J.J., Kropp H., Kahan F.M. Use of acetylacetone to prepare a prodrug of cycloserine. J. Med. Chem. 1980, 23:6-8.
60. Bodor, N. S., Sloan, K. B., Hussain, A. A., Novel transient pro-drug forms of L -DOPA, US Patent 3,891,696 (June 24, 1975; Inter'X Res. Corpn.) 1975.
61. Koch H. ST-1059. Drugs Fut 1981, 6:244-246.
62. Vicentini C.B., Guarneri M., Sarto G. Hypoglycemic compounds. Sulfonylurea derivatives containing amino acids and dipeptides,. Farmaco, Ed. Sci. 1983, 38:595-608.
63. Rubenstein S.M., Baichwal V., Beckmann H., Clark D.L., Frankmoelle W., Roche D., Santha E., Schwender S., Thoolen M., Ye Q., Jaen J.C. Hydrophilic, pro-drug analogues of T138067 are efficacious in controlling tumor growth in vivo and show a decreased ability to cross the blood brain barrier. J. Med. Chem. 2001, 44:3599-3605.
64. Boehringer, Dérivés de la L-(3,4-dihydroxy-phényl)-2-méthyl alanine et leur préparation, Belg. Pat. 839,362 (March 9, 1976 to Boehringer Mannheim GMBH), 1976.
65. Kingsbury W.D., Boehm J.C., Mehta R.J., Grappel S.F. Transport of antimicrobial agents using peptide carrier systems: anticandidal activity of m -fluorophenylalanine peptide conjugates. J. Med. Chem. 1983, 26:1725-1729.
66. Hu M., Subramanian P., Mosberg H.I., Amidon G.L. Use of the peptide carrier system to improve the intestinal absorption of l-α-methyldopa: carrier kinetics, intestinal permeabilities, and in vitro hydrolysis of dipeptidyl derivatives of l-α-methyldopa. Pharm. Res. 1989, 6:66-70.
67. Rahmathullah S.M., Hall J.E., Bender B.C., McCurdy D.R., Tidwell R.R., Boykin D.W. Prodrugs for amidines: synthesis and anti- pneumocystis carinii activity of carbamates of 2,5-bis(4-amidinophenyl)furan. J. Med. Chem. 1999, 42:3994-4000.
68. Buur A., Bundgaard H., Falch E. Prodrugs of 5-fluorouracil. VII. Hydrolysis kinetics and physicochemical properties of N -ethoxy- and N -phenoxycarbonylmethyl derivatives of 5-fluorouracil,. Acta Pharm. Suec. 1986, 23:205-216.
69. Larsen J.D., Bundgaard H. Prodrug forms for the sulfonamide group. I. Evaluation of N -acyl derivatives, N -sulfonylamidines, N -sulfonyl- sulfilimines and sulfonylureas as possible prodrug derivatives,. Int. J. Pharm. 1987, 37:87-95.
70. Bundgaard H., Buur A., Hansen K.T., Larsen J.D., Moss J., Olsen L. Prodrugs as drug delivery systems. 77. Phthalidyl derivatives as prodrug forms for amides, sulfonamides, carbamates and other NH-acidic compounds,. Int. J. Pharm. 1988, 45:47-57.
71. Hardcastle G.A., Johnson D.A., Panetta C.A., Scott A.I., Sutherland S.A. The preparation and structure of hetacillin. J. Org. Chem. 1966, 31:897-899.
72. Bundgaard H. Design of prodrugs: bioreversible derivatives for various functional groups and chemical entities. Design of Prodrugs 1985, 1-92. Elsevier, Amsterdam. H. Bundgaard (Ed.).
73. Anonymous. Droxicam. Drugs Fut. 11 (1986) 835-836.
74. Zeller P., Pletscher A., Gey K.F., Gutmann H., Hegedus B., Staub O. Amino acid and fatty acid hydrazides: chemistry and action on monoamine oxidase. Ann. NY Acad. Sci. 1959, 80:555-567.
75. Knapp F.F.J., Goodman M.M., Callahan A.P., Ferren L.A., Kabalka G.W., Sastry K.A.R. New myocardial imaging agents: stabilization of radioiodine as a terminal vinyl iodide moiety on tellurium fatty acids. J. Med. Chem. 1983, 26:1293-1300.
76. Wess, G., Kramer, W., Schubert, G., Bickel, M., Hoffmann, A.,Baringhaus, K. H. Coupling of drugs to modified bile acids for liver specific targeting. Abst. Pap.205th Meeting of the American Chemical Society. 1993, 16. Pt. 1, MEDI 152.
77. Nagy A., Schally A.V. Targeted cytotoxic somatostatin analogs: a modern approach to the therapy of various cancers. Drugs Fut 2001, 26:261-270.
78. Biel J.H., Martin Y.C. Organic synthesis as a source of new drugs. Drug Discovery-Science and Development in a Changing Society 1971, Vol. 108:81-111. American Chemical Society, Washington, DC. A.C. Society (Ed.).
79. Whittaker J.R. Biosynthesis of a thiouracil pheomelanin in embryonic pigment cells exposed to thiouracil. J. Biol. Chem. 1971, 246:6217-6226.
80. Dencker L., Larsson B., Olander K., Ullberg S., Yokota M. False precursors of melanin as selective melanoma seekers. Br. J. Cancer 1979, 39:449-452.
81. Wätjen F., Buchardt O., Langvad E. Affinity therapeutics. 1. Selective incorporation of 2-thiouracil derivatives in murine melanomas. Cytostatic activity of 2-thiouracil arotinoids, 2-thiouracil retinoids, arotinoids and retinoids,. J. Med. Chem. 1982, 25:956-960.
82. Ariëns E.J. Modulation of pharmacokinetics by molecular manipulation. Drug Des 1971, Vol. II:1-127. Academic Press, New York. E.J. Ariëns (Ed.).
83. Ariëns, E. J. Pharmacological basis of cancer therapy, In Twenty- Seventh Annual Symposium on Fundamental Cancer Research. The University of Texas M.D. Anderson Hospital and Tumor Institute at Houston, 1974; The Williams and Wilkins Company, Baltimore, MD, 1975.
84. Hurwitx E., Kashi R., Burowsky D., Arnon R., Haimovitch J. Sitedirected chemotherapy with a drug bound to anti-idiotypic antibody to a lymphoma cell-surface IgM. Int. J. Cancer 1983, 31:745-748.
85. Magnan S.D.J., Shirota F.N., Nagasawa H.T. Drug latentiation by γ-glutamyl transpeptidase. J. Med. Chem. 1982, 25:1018-1021.
86. Wilk S., Mizoguchi H., Orlowski M. Gamma-glutamyl-DOPA: a kidney specific dopamine precursor. J. Pharmacol. Exp. Ther. 1978, 206:227-232.
87. Kyncl J.J., Minard F.N., Jones P.H. Peripheral dopamine receptors. Symposium on Peripheral Dopaminergic Receptors-Strasbourg, July 1978 1979, 369-380. Pergamon Press, Oxford. J.L. Imbs, J. Schwartz (Eds.).
88. Jones, P. H., Kyncl, J., Ours, C. W., Somani, P. Esters of γ-glutamylamide of dopamine. US Patent. 4,017,636 (12 April 1977, to Abott Laboratories) 1977.
89. Orlowski M., Mizoguchi H., Wilk S. N-acyl-γ-glutamyl derivatives of sulfamethoxazole as models of kidney-selective prodrugs. J. Pharmacol. Exp. Ther. 1979, 212:167-172.
90. Friend D.R., Chang G.W. Drug glycosides: potential prodrugs for colon-specific drug delivery. J. Med. Chem. 1985, 28:51-57.
91. Friend D.R., Chang G.W. A colon-specific drug-delivery system based on drug glycosides and the glycosidases of colonic bacteria. J. Med. Chem. 1984, 27:261-266.
92. Cook A.F., Holman M.J., Kramer M.J., Trown P.W. Florinated pyrimidine nucleosides. 3. Synthesis and antitumor activity of a series of 5'-deoxy-5fluoropyrimidine nucleosides,. J. Med. Chem. 1979, 22:1330-1335.
93. Au J., -S.Walker L., Rustum J.S. Y. Pharmacokinetic studies of 5-fluorouracil and 5'-deoxy-5-fluorouridine in rats. J. Pharmacol. Exp. Ther. 1983, 227:174-180.
94. de Groot F.M.H., van Berkom L.W.A., Scheeren H.W. Synthesis and biological evaluation of 2'-carbamate-linked and 3'-carbonate-linked prodrugs of paclitaxel: selective activation by the tumor-associated protease plasmin. J. Med. Chem. 2000, 43:3093-3102.
95. Stella V.J., Charman W.N.A., Naringrekar V.H. Prodrugs do they have advantages in clinical practice?. Drugs 1985, 29:455-473.
96. Sinkula A.A. Sustained drug action accomplished by the prodrug approach. Design of Prodrugs 1985, 157-176. Elsevier, Amsterdam. H. Bundgaard (Ed.).
97. ® in 3 women. Hormone Res 1983, 17:84-89.
98. Falconi G., Galetti F., Celasco G., Gardi R. Oral long-lasting estrogenic activity of estradiol 3-benzoate 17-cyclooctenyl ether. Steroids 1972, 20:627-632.
99. Ercoli A., Gardi R. D4-3-keto steroidal ethers. Paradoxical dependency of their effectiveness on the administration route,. J. Am. Chem. Soc. 1960, 82:746-748.
100. Cain B.F. The role of structure-activity studies in the design of antitumor agents. Cancer Chemother. Rep. 1975, 59(4):679-683.
101. Cain B.F. 2-Acyloxymethylbenzoic acids. Novel amine protective functions providing amides with the lability of esters,. J. Org. Chem. 1976, 41(11):2029-2031.
102. Sakamoto F., Ikeda S., Tsukamoto G. Studies on prodrugs. II. Preparation and characterization of (5-substituted 2-oxo-1,3-dioxolen-4-yl)methyl esters of ampicillin,. Chem. Pharm. Bull. 1984, 32:2241-2248.
103. Bundgaard H. Novel chemical approaches in prodrug design. Drugs Fut 1991, 16:443-458.
104. Borgman R.J., Smith R.V., Keiser J.E. The acetylation of apomorphine. An improved method for the selective preparation of diacetylapomorphine utilizing trifluoroacetic acid/acetyl bromide,. Synthesis 1975, 249-250.
105. Nicolaou K.C., Riemer C., Kerr M.A., Rideout D. Wrasidlo. W. Design, synthesis and biological activity of protaxols, Nature (London) 1993, 364:464-466.
106. Nicolaou K.C., Guy R.K., Pitsinos E.N., Wrasidlo W. A watersoluble prodrug of taxol with self-assembling properties. Angew. Chem. Int. Ed. 1994, (in press).
107. Norbeck D.W., Rosenbrook W., Kramer J.B., Grampovnik D.J., Lartey P.A. A novel prodrug of an impermeant inhibitor of 3-deoxy- d -manno-2-octulosonate cytidylyl-transferase has antibacterial activity. J. Med. Chem. 1989, 32:625-629.
108. Bundgaard H., Falch E., Larsen C., Mikkelson T.J. Pilocarpine prodrugs Synthesis, stability, bioconversion, and physicochemical properties of sequentially labile pilocarpine acid diesters. J. Pharm. Sci. 1986, 75:36-44.
109. Bundgaard H., Falch E., Larsen C., Mosher G.L., Mikkelson T.J. Pilocarpine prodrugs II. Synthesis, stability, bioconversion and physicochemical properties of sequentially labile pilocarpine acid diesters,. J. Pharm. Sci. 1986, 75:775-783.
110. Amsberry K.L., Borchardt R.T. Amine prodrugs which utilize hydroxy-amide lactonization. I. A potential redox-sensitive amide prodrug,. Pharm. Res. 1991, 8:323-330.
111. Amsberry K.L., Gerstenberger A.E., Borchardt R.T. Amine prodrugs which utilize hydroxy-amide lactonization. II. A potential esterase-sensitive prodrug,. Pharm. Res. 1991, 8:455-461.
112. Leppänen J., Huuskonen J., Nevalainen T., Gynther J., Taipale H., Järvinen T. Design and synthesis of a novel L -dopa-entacapone codrug. J. Med. Chem 2002, 45:1379-1382.
113. Bodor N.S. Novel approaches for the design of membrane transport properties of drugs. Design of biopharmaceutical properties through prodrugs and analogs 1977, 98-135. American Pharmaceutical Association, Washington, DC. E.B. Roche (Ed.).
114. Bodor N.S., Kaminski J.J., Selk S. Soft drugs. 1. Labile quaternary ammonium salts as soft antimicrobials,. J. Med. Chem. 1980, 23:469-474.
115. Bodor N.S., Kaminski J.J. Soft drugs. 2. Soft alkylating compounds as potential antitumor agents,. J. Med. Chem. 1980, 232:566-569.
116. Bodor N.S., Woods R., Raper C., Kearney P., Kaminski J.J. Soft drugs. 3. A new class of anticholinergic agents,. J. Med. Chem. 1980, 23:474-480.
117. Bodor N. Prodrugs versus soft drugs. Design of Prodrugs 1985, 333-354. Elsevier, Amsterdam. H. Bundgaard (Ed.).
118. Peacock J.E., Francis G. Remifentanyl pharmacokinetics and metabolism. Drugs Today 1997, 33:611-618.
119. Benfield P., Sorkin E.M. Esmolol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy,. Drugs 1987, 392-412.
120. Pitman I.H. Pro-drugs of amides, imides, and amines. Med. Res. Rev. 1981, Vol. 1:189-214. John Wiley & Sons, New York. G. deStevens (Ed.).
121. Carini D.J., Duncia J.V., Aldrich P.E., Chiu A.T., Johnson A.U., Piera M.E., Price W.A., Santellar J.B.r., Wells G.J., Wexler R.R., Wong P.C., Yoo S.-E., Timmerman P.B. Non-peptide angiotensin II antagonists: the discovery of a series of N -(biphenylmethyl) imidazoles as potent, orally active antihypertensives. J. Med. Chem. 1991, 34:2525-2547.
122. Wong P.C., Price W.A.J., Chiu A.T., Duncia J.V., Carini D.J., Wexler R.R., Johnson A.L., Timmerman P.B. Non-peptide angiotensin II receptor antagonists. XI. Pharmacology of Exp 3174: an active metabolite of DuP 753, an orally activeantihypertensive agent,. J. Pharmacol. Exp. Ther. 1990, 255:211-217.
123. Baldessarini R.J., Neumeyer J.L., Campbell A., Sperk G., Ram V.J., Arana G.W., Kula N.S. An orally effective, longacting dopaminergic prodrug: (-)-10,11-methylenedioxy- N - propylnorapomorphine. Eur. J. Pharmacol. 1982, 77:87-88.
124. Venhuis B.J., Wikström H.V., Rodenhuis N., Sundell S., Dijkstra D. A new type of prodrug of catecholamines: an opportunity to improve the treatment of Parkinson's disease. J. Med. Chem. 2002, 45:2349-2351.
125. Savi P., Pereillo J.M., Uzabiaga M.F., Combalbert J., Picard C., Maffrand J.P., Pascal M., Herbert J.M. Identification and biological activity of the active metabolite of clopidogrel. Thromb. Haemostasis 2000, 84:891-896.
126. Clarke T.A., Waskell L.A. The mechanism of clopidogrel is catalyzed by human cytochrome P450 3Aand is inhibited by atorvastatin. Drug Metab. Dispos. 2003, 31:53-59.
127. Bodor N., Shek E., Higuchi T. Improved delivery through biological membranes. 1. Synthesis and properties of 1-methyl-1,6-dihydropyridine-2-carbaldoxime, a pro-drug of N -methylpyridinium-2-carbaldoxime chloride,. J. Med. Chem. 1976, 19:102-107.
128. Shek E., Higuchi T., Bodor N. Improved delivery through biological membranes. 2. Distribution, excretion, and metabolism of N -methyl-1,6-dihydropyridine-2-carbaldoxime hydrochloride, a pro-drug of N -methylpyridinium-2-carbaldoxime chloride,. J. Med. Chem. 1976, 19:108-112.
129. Shek E., Higuchi T., Bodor N. Improved delivery through biological membranes. 3. Delivery of N -methylpyridinium-2-carbaldoxime chloride through the blood-brain-barrier in its dihydropyridine prodrug form,. J. Med. Chem. 1976, 19:113-117.
130. Krenitsky T.A., Hall W.W., de Miranda P., Beauchamp L.M., Schaeffer H.J., Whiteman P.D. Deoxyacyclovir: a xanthine oxidase-acitvated prodrug of acyclovir. Proc. Natl. Acad. Sci. USA 1984, 31:3209-3213.
131. Whiteman P.D., Bye A., Fowle A.S.E., Jeal S., Land G., Posner J. Tolerance and pharmacokinetics of A515U, an acyclovir analogue in healthy volunteers. Eur. J. Clin. Pharmacol. 1984, 27:471-475.
132. Gershwin M.E., Goetzl E.J., Steinberg A.D. Cyclophosphamide: use in practice. Ann. Int. Med. 1974, 80:531-540.
133. Silverman R.B. The Organic Chemistry of Drug Design and Drug Action 1992, Academic Press, San Diego, CA, p. 380.
134. Zon G. Cyclophosphamide analogues. Progress in Medicinal Chemistry 1982, 205-246. Elsevier, Amsterdam. G.P. Ellis, G.B. West (Eds.).
135. Arnold H., Bourseaux F., Brock N. NeuartigeKrebs-Chemotherapeutika aus der Gruppe der zyklischen N -Lostphosphamidester. Naturwissenschaften 1958, 45:64-66.
136. Arnold H., Bourseaux F., Brock N. Chemotherapeutic action of a cyclic nitrogen mustard phosphamide ester (B518-ASTA) in experimental tumors of the rat. Nature 1958, 181:931.
137. Arnold H. Ueber die Chemie neuer zytostatisch wirksamer N - Chloroaethyl-phosphorsäureesterdiamide. Proceedings of the Fifth International Congress on Chemotherapy 1967, 751-754. Verlag der Wiener Medizinischen Akademie, Wien. K. Spitzy, H. Haschek (Eds.).
138. Kennedy K.A., Teicher B.A., Rockwell S., Sartorelli A.C. The hypoxic tumor cell: a target for selective cancer chemotherapy. Biochem. Pharmacol. 1980, 29:1-8.
139. Davis P.J., Guenthner L.E. Sulindac oxidation/reduction by microbial cultures; microbial models for mammalian metabolism. Xenobiotica 1985, 15:845-857.
140. Kwon C.-H., Blanco D.R., Baturay N. p -(Methylsulfinyl)phenyl nitrogen mustard as a novel bioreductive prodrug selective against hypoxic tumors. J. Med. Chem. 1992, 35:2137-2139.
141. Cole C., Reigan P., Gbaj A., Edwards P.N., Douglas K.T., Stratford I.J., Freeman S., Jaffar M. Potential tumor-selective nitroimidazolylmethyluracil prodrug derivatives: inhibitors of the angiogenic enzyme thymidine phosphorylase. J. Med. Chem. 2003, 46:207-209.
142. 1)-ATPase within the parietal cell. Biochim. Biophys. Acta 1984, 778:549-558.
143. Lamers C.B.H.W., Lind T., Moberg S., Jansen J.B.M., OIbe L. Omeprazole in Zollinger-Ellison Syndrome. New Engl. J. Med. 1984, 310:758-761.
144. +-activated oxidizing agent of sulfhydryl groups. J. Biol. Chem. 1985, 260:4591-4597.
145. Lindberg P., Nordberg P., Alminger T., Brändström A., Wallmark B. The mechanism of action of the gastric acid secretion inhibitoromeprazole. J. Med. Chem. 1986, 33:1329-1685.
146. Krausz F., Demarne H., Vaillant J., Brunaud M., Navarro J. Anti-inflammatoires non stéroidiques: Dérivés de l'acide phényl-4-butyrique et phényl-4, oxo-4, butyrique. Arzneim.-Forsch. (Drug Res.) 1974, 24(9a):1360-1364.
147. Gros P.M., Davi H.J., Chasseaud L.F., Hawkins D.R. Metabolic and pharmacokinetic study of bucloxic acid. Arzneim.-Forsch. (Drug Res.) 1974, 24(9a):1385-1390.
148. Kohler C., Tolman E., Wooding W., Ellenbogen L. A review of the effects of fenbufen and a metabolite, biphenylacetic acid, on platelet biochemistry and function. Arzneim.-Forsch. (Drug Res.), 1980, 30:702-707.
149. Chicarelli F.S., Eisner H.J., Van Lear G.E. Disposition and metabolism of fenbufen in several laboratory animals. Arzneim.-Forsch. (Drug Res.), 1980, 30:707-715.
150. Martel R.R., Rochefort J.G., Klicius J., Dobson T.A. Antiinflammatory properties of furobufen. Can. J. Physiol. Pharmacol. 1974, 52:669-673.
151. Gilard J.W., Belanger P. Metabolic synthesis of arylacetic acid antiinflammatory drugs from arylhexenoic acids. 2. Indomethacin,. J. Med. Chem. 1987, 30:2051-2058.
152. Williamson J.M., Meister A. Stimulation of hepatic glutathione formation by administration of l -2-oxothiazolidine-4-carboxylate, a 5-oxo- l -prolinase substrate. Proc. Natl. Acad. Sci. USA 1981, 78(2):936-939.
153. Matsukawa T., Yuruki S., Oka Y. The synthesis of S -acylthiamine derivatives and their stability. Ann. NY Acad Sci. 1962, 98:430-444.
154. Thomson A.D., Frank O., Baker H., Leevy C.M. Thiamine propyl disulphide: absorption and utilization. Ann. Int. Med. 1971, 74:529-534.
155. Bodor N., Farag H.H., Brewster.M.E. Site-specific, sustained release of drugs to the brain. Science 1981, 214:1370-1372.
156. Cousse H., Casadio S., Mouzin G. L'hydroxy éthyl nicotinamide vecteur d'acides thérapeutiquement actifs. Trav. Soc. Pharm. Montpellier 1978, 38:71-76.
157. Casadio, S., Cousse, H., Mouzin, G. Nouvelles formes modulées de médicaments utilisant les N -hydroxy alcoyl pyridine carboxamides comme vecteur. Fr. Pat.NO. 77.13478 (May 2, 1977, to P. Fabre S.A.) 1977.
158. Vezin J.C., Mouzin G., Cousse H., Casadio S. Nicafenine, a new analgesic. Arzneim.-Forsch. 1979, 29:1659-1661.
159. Gorrod J.W. Potential hazards of the pro-drug approach. Chem. Ind. 1980, 457-461.
160. Roberts J.C., Nagasawa H.T., Zera R.T., Fricke R.F., Goon D.J.W. Prodrugs of l -cysteine as protective agents against acetaminophen-induced hepatotoxicity. 2-(Polyhydroxyalkyl)- and 2-(polyacetoxyalkyl)thiazolidine-4(R)-carboxylic acids,. J. Med. Chem. 1987, 30:1891-1896.
161. Saari W.S., Freedman M.B., Hartman R.D., King S.W., Raab A.W., Randall W.C., Engelhart E.L., Hirschmann R., Rosegay A., Ludden C.T., Scriabine A. Synthesis and antihypertensive activity of some ester progenitors of methyldopa. J. Med. Chem. 1978, 21:746-753.
162. Vickers S., Duncan C.A., White S.D., Breault G.O., Boyds R.B., Shepper d.P.J., Tempero K.F. Evaluation of succinimidoethyl and pivaloyloxyethyl esters as progenitors of methyldopa in man, rhesus monkey, dog, and rat. Drug Metab. Dispos. 1978, 6:640-646.